Avoid Mishaps With SGLT2 Inhibitors

September 2022

More inpatients will get SGLT2 inhibitors...canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin.

These meds were originally approved for type 2 diabetes. But now they’re also recommended for certain patients with heart failure.

Avoid mishaps with SGLT2 inhibitors as use increases.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote